Tumores de tronco cerebral en la población pediátrica

Villarejo, F.; Ferrara, M; Belinchón, J.M.; Madero, Luís; Rivero, B.; Cordobés, F.; Pascual, Alexandre; Pérez-Diaz, Carlos; Prada, Inmaculada de

doi:10.1016/s1130-1473(08)70204-5

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the most common macroscopic findings on imaging techniques for DMG include necrosis in one in five cases, growth from the cephalocaudal direction towards the midbrain, cerebral peduncles, cerebellum or medulla oblongata, and poorly defined margins [ 10 , 26 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology, Diagnostic Strategies, and Therapeutic Advances in Diffuse Midline Glioma

Miguel Llordes,

Medina Pérez,

Curto Simón

et al. 2023

JCM

View full text Add to dashboard Cite

Object: Diffuse midline glioma (DMG) is a highly aggressive and lethal brain tumor predominantly affecting children and young adults. Previously known as diffuse intrinsic pontine glioma (DIPG) or grade IV brain stem glioma, DMG has recently been reclassified as “diffuse midline glioma” according to the WHO CNS5 nomenclature, expanding the DMG demographic. Limited therapeutic options result in a poor prognosis, despite advances in diagnosis and treatment. Radiotherapy has historically been the primary treatment modality to improve patient survival. Methods: This systematic literature review aims to comprehensively compile information on the diagnosis and treatment of DMG from 1 January 2012 to 31 July 2023. The review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and utilized databases such as PubMed, Cochrane Library, and SciELO. Results: Currently, molecular classification of DMG plays an increasingly vital role in determining prognosis and treatment options. Emerging therapeutic avenues, including immunomodulatory agents, anti-GD2 CAR T-cell and anti-GD2 CAR-NK therapies, techniques to increase blood–brain barrier permeability, isocitrate dehydrogenase inhibitors, oncolytic and peptide vaccines, are being explored based on the tumor’s molecular composition. However, more clinical trials are required to establish solid guidelines for toxicity, dosage, and efficacy. Conclusions: The identification of the H3K27 genetic mutation has led to the reclassification of certain midline tumors, expanding the DMG demographic. The field of DMG research continues to evolve, with encouraging findings that underscore the importance of highly specific and tailored therapeutic strategies to achieve therapeutic success.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In the past decade, the primary method for diagnosing DMG has been magnetic resonance imaging (MRI) [ 1 , 2 , 3 , 4 , 10 ]. The tumor grows within the brain stem, responsible for vital functions like breathing, heart rate, and blood pressure.…”

Section: Introductionmentioning

confidence: 99%